Medical Marijuana, Inc. Proudly Supports Research into Difficult to Treat Medical Conditions

[vc_row][vc_column][vc_column_text]Medical Marijuana, Inc. and our portfolio of investment companies are using cannabinoids to research potential new treatments for a range of medical conditions, including those that have proven notoriously hard to treat. Additionally, we regularly make donations to nonprofits working to find a cure to some of the world’s most troublesome medical indications.

Not only will this research ultimately improve the quality of life for those suffering from these conditions, but it gives cannabis advocates the fuel they need to press local, state, and national governments to act on cannabis reform by revealing its medical potential.

Here are just a few of the ways our company is encouraging critically needed medical research.

Kannalife™ Sciences Capitalizes on Government’s Patent on Cannabinoids

Kannalife™ Sciences, one of Medical Marijuana, Inc.’s investment companies, is applying their licenses on the government’s patent 6,630,507, Cannabinoids as antioxidants and neuroprotectants, to create novel new drugs for entry into the pharmaceutical market. Kannalife™’s current research centers on of a pair of degenerative neurological diseases, HE and CTE.

Hepatic encephalopathy (HE) occurs when the liver is fails to function adequately. This allows toxins to reach the brain, reducing its functionality. These same toxins, like ammonia, can be transported throughout the bloodstream, damaging the nervous system. HE typically results in those with chronic liver disease, sometimes caused by addiction to alcohol or pharmaceutical drugs.

Chronic traumatic encephalopathy or CTE is the consequence of repeated blows to the head. Directly linked to the trauma from concussions, CTE is estimated to affect over 90% of NFL players. However, the condition may be found in anyone with severe or recurrent head injuries. While diagnosis can only be positively made after death with an autopsy, symptoms become noticeable until about eight to 10 years after the outset of the disease and include memory loss, confusion, impaired judgment, impulse control problems, depression, aggression, and dementia.

Although Kannalife™ Sciences is focusing on developing drugs for these two conditions in their research now, the company’s work can open up the discovery of treatments for a number of other neurodegenerative diseases, like Parkinson’s or Alzheimer’s disease.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_single_image image=”17365″ img_size=”1200×250″ onclick=”custom_link” link=””][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]

AXIM® Biotechnologies Plans Clinical Trials on Nine Cannabis-Based Drugs

Similarly, AXIM® Biotechnologies, another Medical Marijuana, Inc. investment company, has built an impressive list of medical indications for which is it testing its products, pushing forward the boundaries of cannabinoid treatments. AXIM® is innovating a variety of application methods for its new cannabinoid-based medications, including its patented time-released gum, suppositories, and topically applied salve.

The company has scheduled or started clinical trials for conditions such as Crohn’s disease, restless leg syndrome, dementia, psychosis, Parkinson’s disease, the pain and spasticity associated with multiple sclerosis, irritable bowel syndrome, psoriasis and eczema, and glaucoma. AXIM® is planning on running clinical trials on a total of nine new drugs with the earliest new drug applications coming in 2018.

AXIM® Biotechnologies recently filed an intellectual property application for their proprietary method for the extraction and purification of cannabinoids. This process creates cannabinoids with a purity of 98 percent or higher, allowing the company to develop pharmaceutical grade cannabinoid treatments.

Donations to Hope4Harper Fund Neurological Research

Cherished members of what we consider to be the Medical Marijuana, Inc. extended family, the Howards have long been vocal advocates for the benefits of cannabinoids like CBD. The family even started the not-for-profit Hope4Harper to help build awareness for CBD and raise funds to support medical research. Sadly, the family lost their daughter Harper this past winter, electing to make a donation of her organs and tissue to ongoing neurological research. However, their loss has not dimmed their passion for giving back. In fact, it has only invigorated the family’s drive to support this crucial research.

For the past five years, the family has organized their annual Run4Hope charity run to raise money for neurological research. As in the past, Medical Marijuana, Inc. subsidiary HempMeds® participated in the event this September and made a $10,000 donation to Hope4Harper to help the organization fund their targeted research.

The family is currently working to fund research in Boston and in our own backyard at the Muotri Lab at UC San Diego using their daughter’s organ and tissue donations to search for treatments for neurological diseases like epilepsy. At the Muotri Lab, Dr. Muotri is using Harper’s cells to grow mini-brains to test various potential treatments for degenerative conditions. [/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_single_image image=”17189″ img_size=”1200×350″][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]Through our portfolio of investments, Medical Marijuana, Inc. continues support cannabinoid-based medical research around the world. Read more about Medical Marijuana, Inc.’s commitment to medical research on our news feed.[/vc_column_text][/vc_column][/vc_row]